Dementia in China: Current status

Liu, Jia; Wang, Luning; Tan, Jiping

doi:10.1212/wnl.0b013e3182a4a3cb

Cited by 27 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that by 2050, the elderly will account for 30.4 % of the total population in China [1]. This aging will be accompanied by an increased incidence of chronic disease such as vascular dementia (VD), which is associated with disability, institutionalization, and mortality among elderly individuals.…”

Section: Introductionmentioning

confidence: 99%

Preconditioning with VEGF Enhances Angiogenic and Neuroprotective Effects of Bone Marrow Mononuclear Cell Transplantation in a Rat Model of Chronic Cerebral Hypoperfusion

Wang

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

Bone marrow mononuclear cell (BMMNC) transplantation is a promising therapy for brain ischemia. However, BMMNCs are few in number, and a limited time window is available during which they can penetrate the blood–brain barrier (BBB) and migrate to the brain. We investigated whether vascular endothelial growth factor (VEGF) can facilitate BMMNC migration into the ischemic brain and enhance their therapeutic effect in a rat model of chronic cerebral hypoperfusion. First, we assessed the impact of VEGF on the BBB of rats that had undergone permanent bilateral occlusion of the common carotid arteries (2VO). Then, we transplanted BMMNCs into 2VO rats pretreated with intracerebroventricular VEGF or vehicle. We examined cognitive function with the Morris water maze test, BMMNC migration by immunofluorescence analysis, and cytokine levels in the peripheral blood by enzyme-linked immunosorbent assay (ELISA). Angiogenesis and neural degeneration were evaluated by staining tissue with Ki67/lectin or Fluoro-Jade B. We found that at a dose of 0.2 μg/rat, VEGF significantly increased BBB permeability without causing brain edema in 2VO rats. VEGF+BMMNC-treated rats had more BMMNC migration in the ischemic brain, better learning and memory, greater proliferation of vessels, and fewer degenerating neurons than did BMMNC-treated rats. Pretreatment with VEGF receptor inhibitor SU5416 significantly decreased BMMNC migration and abolished the therapeutic effect of BMMNC transplantation. We conclude that preconditioning with an appropriate dose of VEGF can enhance the therapeutic efficacy of BMMNC transplantation in 2VO rats, possibly by facilitating BMMNC migration into the ischemic brain.

show abstract

Section: Introductionmentioning

confidence: 99%

Preconditioning with VEGF Enhances Angiogenic and Neuroprotective Effects of Bone Marrow Mononuclear Cell Transplantation in a Rat Model of Chronic Cerebral Hypoperfusion

Wang

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

show abstract

“…Because of major methodological differences between the local studies that have been published to date, it has not been feasible to derive a cross-country estimate of dementia incidence by integrating these studies. With the accelerated aging trend of the Chinese population (the latest statistics indicate that there are approximately 119 million people aged 65 years) [15,16], representative age-specific, sex-specific incidence rates of dementia in our country, as well as statistical comparisons of urbanrural, northern-southern, and eastern-western differences, are needed to target interventions and develop preventive strategies. Hence, to better characterize the overall epidemiologic profile of dementia in China, we conducted a population-based, prospective, cohort study in four geographically representative major regional centers in China, using extensive case ascertainment procedures.…”

Section: Introductionmentioning

confidence: 99%

Incidence of dementia and subtypes: A cohort study in four regions in China

Yuan

Zhang

Wen

et al. 2015

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…and more than 20 % will live in China [1]. AD is estimated to account for approximately 50-80 % of all dementias [2].…”

mentioning

confidence: 99%

Peroxisome Proliferator-Activated Receptor-Gamma Agonists for Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis

2014

View full text Add to dashboard Cite

There is insufficient evidence to support the use of rosiglitazone in aMCI and AD patients in order to improve cognitive performance. Nonetheless, the efficacy of pioglitazone seems to be promising, particularly for patients with comorbid diabetes, however this needs to be further confirmed by well-designed trials with large sample sizes. PPAR-γ agonists such as rosiglitazone and pioglitazone are generally well-tolerated in AD and aMCI patients.

show abstract

Dementia in China: Current status

Cited by 27 publications

References 11 publications

Preconditioning with VEGF Enhances Angiogenic and Neuroprotective Effects of Bone Marrow Mononuclear Cell Transplantation in a Rat Model of Chronic Cerebral Hypoperfusion

Preconditioning with VEGF Enhances Angiogenic and Neuroprotective Effects of Bone Marrow Mononuclear Cell Transplantation in a Rat Model of Chronic Cerebral Hypoperfusion

Incidence of dementia and subtypes: A cohort study in four regions in China

Peroxisome Proliferator-Activated Receptor-Gamma Agonists for Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About